AIXC Stock Forecast: AIxCrypto Holdings, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 7 of 100 as at 1 Aug 2026 — in the weakest quartile.
AIXC stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores AIxCrypto Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (90): Smaller than most of the companies we track.
Value (4): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own AIxCrypto Holdings, Inc. — and when they’d sell — is the membership.
AIXC stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on AIXC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
AIXC analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
AIxCrypto Holdings, Inc. (AIXC) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 0.4×
- Price / sales
- 3.1×
- Price / book
- 0.2×
- EV / EBITDA
- 0.9×
Cheaper than 71% of US stocks
Cheaper than 40% of US stocks
Cheaper than 88% of US stocks
Cheaper than 58% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −382.1%
- Net margin
- 0.0%
Higher than 9% of US stocks
Higher than 30% of US stocks
- Return on equity
- −237.0%
- Return on assets
- −42.5%
- Dividend yield
- —
Higher than 6% of US stocks
Higher than 9% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
AIXC vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AIXC appears on the weeks it earns a place.
Frequently asked questions about AIXC stock
How does Ticker Nerd's model rank AIXC?
As at 1 Aug 2026, AIxCrypto Holdings, Inc. ranks 7 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (90 of 100).
What is the AIXC stock forecast for 2030?
No analyst covering AIxCrypto Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AIXC are extrapolating price history, which says nothing about the business.
How has AIXC stock performed over the past year?
AIxCrypto Holdings, Inc. returned -63.7% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does AIxCrypto Holdings, Inc. do?
Qualigen Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases.
About AIxCrypto Holdings, Inc.
Qualigen Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases. Its pipeline includes lead candidate QN-302, an investigational small molecule G-quadruplex-selective transcription inhibitor in Phase 1 clinical trials for pancreatic cancer and other solid tumors. The company is also advancing Pan-RAS in preclinical stages for advanced solid tumors, along with other programs such as QN-247, an oligonucleotide-based drug for nucleolin-expressing cancers; QN-165 for broad-spectrum infectious diseases; RAS-F, a small-molecule inhibitor targeting RAS mutations; and STARS, a selective target antigen removal system to eliminate circulating tumor cells, viruses, and immune checkpoints. Additionally, it offers FastPack, a rapid onsite immunoassay testing system leveraging proprietary nanoparticle technology. Qualigen Therapeutics Inc. targets unmet needs in oncology and infectious disease markets, aiming to deliver innovative treatments through advanced drug candidates and diagnostic tools. Founded in 1996 and headquartered in Carlsbad, California, the company operates in the competitive biopharmaceutical sector with a focus on clinical development and commercialization.
CEO Mr. Jiawei Wang · 10 employees · United States · https://www.aixcrypto.ai